Skip to main content
Assets
Boston Scientific logo
BSX.NYSE
Boston Scientific
Health Care · Health Care Equipment

Medical technology company developing devices for cardiology, endoscopy, urology, neuromodulation, and other specialty procedures.

HQ: United StatesListed: United States

Profile & Fundamentals

Boston Scientific: Company identity, ownership, reported financial performance, balance sheets, and corporate actions.

Profile & Fundamentals

Boston Scientific Profile & Fundamentals

Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.

Interactive annual chartsAI financial reviewsReported source tables
Explore this pageJump to a Profile & Fundamentals section

Explore this research

Profile & Fundamentals contents

Company and Market Context

Company Profile & Ownership

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

BSX.NYSE

Company profile record

Boston Scientific Corp

Common Stock · Health Care · Health Care Equipment

Official website

Company

Company / asset
Boston Scientific Corp
Security type
Common Stock
Sector
Health Care
Industry
Health Care Equipment
HQ
🇺🇸 United States
Head office
300 Boston Scientific Way, Marlborough, MA, United States, 01752-1234

Leadership & scale

Chief executive
Mr. Michael F. Mahoney
CEO year born
1965
Full-time employees
59K
Fiscal year end
December
IPO date
1992-05-18

Fundamentals snapshot

Updated 2026-09-27
Market Cap
USD 62.6B
P/E
17.1x
Revenue (Q2 26)
USD 5.4B
Profit (Q2 26)
USD 907.0M
Dividend Yield
--
Revenue (FY 25)
USD 20.1B
Shares in public float
1.4B
Insider ownership
0.25%

Reporting & identifiers

Symbol
BSX.NYSE
Listing
🇺🇸 United States | Dividend Tax: 30%
Ticker Currency
USD
Income Statement Currency
USD
Balance Sheet Currency
USD
Cash Flow Currency
USD
EPS Currency
USD
Contract Type
SPOT
ISIN
US1011371077
Asset ID
equity_55b13a19-f596-5d01-addd-94c29b3953c9

Ownership

Shares Outstanding

Latest: 1.5B | Max: 1.5B | Min: 1.4B

Shares Outstanding
1.9B1.4B942.4M471.2M0.00
1.5B
'17
'19
'21
'23
'25
'26

Latest reported ownership snapshot

As of Oct 1, 2026

Float Shares

97.31%

1.4B latest reported shares

Insider Ownership

0.25%

Latest reported insider stake

Short Float

0.03%

Latest reported short interest / float

Top Holders

Top 5 concentration: 29.05%
BlackRock Inc
institution
Filed 2026-03-31 • Change -4.2M (-3.06%)
9.10%(131.8M shares)
Vanguard Capital Management, LLC
institution
Filed 2026-03-31 • Change +96.4M (0.00%)
6.65%(96.4M shares)
FMR Inc
institution
Filed 2026-03-31 • Change -23.2M (-23.78%)
5.12%(74.2M shares)
State Street Corp
institution
Filed 2026-03-31 • Change +2.1M (+3.25%)
4.69%(68.0M shares)
PRIMECAP Management Company
institution
Filed 2026-06-30 • Change +18.0M (+55.31%)
3.49%(50.5M shares)
Vanguard MStar Total Stk Mkt Idx Invest
fund
Filed 2026-08-31 • Change -87.8K (-0.19%)
3.26%(47.2M shares)
Vanguard 500 Index Investor
fund
Filed 2026-08-31 • Change +468.5K (+1.20%)
2.72%(39.5M shares)
Source tablesView ownership tables

Shares Outstanding

Annual reported shares outstanding; up to 10 reporting dates.

Scroll the table to see every column.

Shares outstanding — reported values
Reporting dateShares outstanding
2017-01-011,373,300,000
2018-01-011,406,200,000
2019-01-011,413,100,000
2020-01-011,440,600,000
2021-01-011,436,200,000
2022-01-011,442,400,000
2023-01-011,476,900,000
2024-01-011,490,200,000
2025-01-011,495,800,000
2026-01-011,484,900,000

Top Holders

Available reported ownership records.

Scroll the table to see every column.

Largest reported holders
HolderSharesOwnershipReported date
BlackRock Inc131,822,0379.1%2026-03-31
Vanguard Capital Management, LLC96,411,5686.65%2026-03-31
FMR Inc74,226,3955.12%2026-03-31
State Street Corp67,986,8474.69%2026-03-31
PRIMECAP Management Company50,520,9143.49%2026-06-30
Vanguard MStar Total Stk Mkt Idx Invest47,236,9713.26%2026-08-31
Vanguard 500 Index Investor39,489,3842.72%2026-08-31
JPMorgan Chase & Co33,350,1572.3%2026-03-31
Geode Capital Management, LLC33,285,7572.3%2026-03-31
Vanguard PRIMECAP Inv30,883,0392.13%2026-06-30
Vanguard Portfolio Management, LLC29,796,2112.06%2026-03-31
D. E. Shaw & Co LP25,457,4091.76%2026-06-30
Bank of America Corp22,756,6461.57%2026-03-31
Morgan Stanley - Brokerage Accounts22,266,6641.54%2026-03-31
NORGES BANK21,170,0291.46%2026-06-30

Earnings, Profitability & Valuation

Earnings, Profitability & Valuation

Earnings & Revenue

Earnings and Revenue Trajectory

AI Review

Boston Scientific delivered strong revenue of $20.1 billion in fiscal 2025, surging nearly 20% year-over-year as its pioneering heart ablation systems gained rapid global adoption. However, growth slowed to 7.5% in the second quarter of 2026 as competing device makers launched rival systems and an August computer outage briefly disrupted factory shipments. This headline slowdown led management to trim full-year organic growth guidance to around 5% to 6%. Crucially, this deceleration represents a transition toward steady cash generation rather than corporate decay. Trailing twelve-month free cash flow reached a formidable $3.62 billion, proving that patient care generates dependable cash regardless of quarterly noise. Because scheduled cardiovascular procedures are deferred rather than canceled, cleared shipping backlogs will restore recognized earnings into 2027.

Revenue, Net Income, and Free Cash Flow

Latest: USD 20.1B | Max: USD 20.1B | Min: USD -82.0M

RevenueFree Cash FlowNet Income
USD 25.3BUSD 18.4BUSD 11.4BUSD 4.5BUSD 0.00USD -2.5B
20.1B
3.7B
2.9B
'16
'18
'20
'22
'24
'25

Valuation

P/E Ratio (TTM)iPublished valuation snapshots use the earnings basis recorded with each observation. Source tables retain that basis.

Latest: 49x

>100x78x52x26x0x
59x
54x
49x
'21'23'25

Profitability & Margins

Margins and Operating Efficiency

AI Review

Profit margins widened significantly in fiscal 2025, with gross margins climbing to 69% and operating margins reaching nearly 20%. This profitability surge occurred because premium heart implants and specialty catheters carry strong pricing power and cost very little to produce once manufacturing reaches scale. High-margin procedure volume dropped directly to the bottom line. While competitor discounting in electrophysiology and temporary cyber recovery expenses will flatten near-term margins, long-term profitability remains well protected. An enterprise restructuring plan targeting $500 million in annual overhead savings by 2029 will counterbalance pricing pressures. As higher-margin vascular products integrate into global sales channels, operating margins should sustainably stabilize above 22%. over time.

Profitability Margins

Latest: 69.0% | Max: 69.0% | Min: -0.8%

Gross MarginOperating MarginNet Margin
87.2%63.1%39.0%14.9%0.0%-9.2%
69.0%
19.8%
14.4%
'16
'18
'20
'22
'24
'25

Latest Profitability Ratios as of 2025-12-31

Gross Margin

69.0%

Gross profit / revenue

Operating Margin

19.8%

Operating income / revenue

Net Margin

14.4%

Net income / revenue

FCF Margin

18.2%

Free cash flow / revenue

Source tablesView earnings, profitability & valuation tables

Revenue, Net Income, and Free Cash Flow

Annual reported results, using the source statement's recorded USD conversion. Up to 10 reporting periods; missing values are not estimated.

Scroll the table to see every column.

Annual earnings and cash flow
Period endRevenue (USD)Net income (USD)Free cash flow (USD)
2016-12-318,386,000,000347,000,000596,000,000
2017-12-319,048,000,000104,000,0001,107,000,000
2018-12-319,823,000,0001,671,000,000-6,000,000
2019-12-3110,735,000,0004,700,000,0001,375,000,000
2020-12-319,913,000,000-82,000,0001,132,000,000
2021-12-3111,888,000,0001,040,000,0001,316,000,000
2022-12-3112,682,000,000698,000,000914,000,000
2023-12-3114,240,000,0001,593,000,0001,703,000,000
2024-12-3116,747,000,0001,854,000,0002,645,000,000
2025-12-3120,074,000,0002,886,000,0003,658,000,000

Published P/E Ratio

Published valuation snapshots retain each observation's earnings basis.

Scroll the table to see every column.

Published valuation snapshots
Period endP/E (times earnings)Earnings basis
2025-12-3149.35Trailing four quarters
2024-12-3171.83Trailing four quarters
2023-12-3153.63Trailing four quarters
2022-12-3195.62Annual net income
2021-12-3158.66Annual net income

Profitability Margins

Matching annual reporting dates. Values are percentages.

Scroll the table to see every column.

Annual profitability margins
Period endGross margin (%)Operating margin (%)Net margin (%)Free cash flow margin (%)
2016-12-3163.7114.744.147.11
2017-12-3164.8916.851.1512.23
2018-12-3165.9417.6817.01-0.06
2019-12-3164.0815.9543.7812.81
2020-12-3156.256.06-0.8311.42
2021-12-3162.7616.178.7511.07
2022-12-3160.8314.385.57.21
2023-12-3162.0215.3211.1911.96
2024-12-3161.3115.7311.0715.79
2025-12-3169.0119.7814.3818.22

Public data excerpt created by iPulse AI and published by Future Edge Group FZE. Source: eodhd. Snapshot retrieved 2026-09-29.

Use is subject to the iPulse AI Terms of Service and applicable source rights. Missing inputs are not estimated. Full access includes the remaining records, research and interactive tools.

Complete Research Workspace

Unlock the complete Profile & Fundamentals

Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.